CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
2024 · Nature Medicine · 50 citations
https://doi.org/10.1038/s41591-024-03009-3
T
Tuyet‐Hang Pham
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
37
Papers
2.8K
Citations
17
h-index
20
i10-index
Tuyet‐Hang Pham is an academic researcher from AstraZeneca (Netherlands). The author has contributed to research in topics: Asthma and respiratory diseases & IL-33, ST2, and ILC Pathways & Chronic Obstructive Pulmonary Disease (COPD) Research. The author has an h-index of 17, co-authored 32 publications.
Papers by this author
worksAbstract PS2-02-04: Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1557-3265.sabcs25-ps2-02-04
Abstract PS5-05-05: Correlating time to treatment discontinuation with overall survival: real-world data on outcomes for first-line endocrine therapy + CDK4/6 inhibitor in metastatic breast cancer
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1557-3265.sabcs25-ps5-05-05
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat